Published in J Biol Chem on March 21, 2002
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A (2007) 4.05
Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol (2007) 3.18
The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum. Traffic (2008) 3.07
Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest (2008) 2.58
Intestinal lipid absorption. Am J Physiol Endocrinol Metab (2009) 2.41
Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol (2009) 2.00
The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology. Physiol Rev (2012) 1.95
Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol (2003) 1.85
Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog Retin Eye Res (2009) 1.80
The protective and destructive roles played by molecular chaperones during ERAD (endoplasmic-reticulum-associated degradation). Biochem J (2007) 1.74
Role of the gut in lipid homeostasis. Physiol Rev (2012) 1.73
Induction of liver steatosis and lipid droplet formation in ATF6alpha-knockout mice burdened with pharmacological endoplasmic reticulum stress. Mol Biol Cell (2010) 1.70
Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest (2004) 1.67
Cytoplasmic lipid droplets are sites of convergence of proteasomal and autophagic degradation of apolipoprotein B. Mol Biol Cell (2006) 1.67
Molecular processes that handle -- and mishandle -- dietary lipids. J Clin Invest (2008) 1.60
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab (2011) 1.53
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice. Hepatology (2012) 1.49
The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res (2008) 1.48
Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control. Proc Natl Acad Sci U S A (2008) 1.45
Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol (2006) 1.39
Sterol-induced dislocation of 3-hydroxy-3-methylglutaryl coenzyme A reductase from endoplasmic reticulum membranes into the cytosol through a subcellular compartment resembling lipid droplets. J Biol Chem (2010) 1.32
Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One (2009) 1.31
A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology (2010) 1.31
Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes (2008) 1.28
Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. J Clin Invest (2012) 1.28
The many intersecting pathways underlying apolipoprotein B secretion and degradation. Trends Endocrinol Metab (2008) 1.27
Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. J Biol Chem (2010) 1.21
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res (2010) 1.21
Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag (2007) 1.15
Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res (2008) 1.12
FoxO1 integrates insulin signaling to VLDL production. Cell Cycle (2008) 1.12
Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? J Lipid Res (2010) 1.11
Intracellular trafficking and secretion of VLDL. Arterioscler Thromb Vasc Biol (2012) 1.09
Hepatitis C virus utilizes lipid droplet for production of infectious virus. Proc Jpn Acad Ser B Phys Biol Sci (2009) 1.09
The Hsp110 molecular chaperone stabilizes apolipoprotein B from endoplasmic reticulum-associated degradation (ERAD). J Biol Chem (2007) 1.07
Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B. J Biol Chem (2009) 1.07
Sec61p is part of the endoplasmic reticulum-associated degradation machinery. EMBO J (2009) 1.07
Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis (2013) 1.05
Ancient ubiquitous protein-1 mediates sterol-induced ubiquitination of 3-hydroxy-3-methylglutaryl CoA reductase in lipid droplet-associated endoplasmic reticulum membranes. Mol Biol Cell (2012) 1.04
Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. J Gen Virol (2004) 1.03
Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion. J Biomed Res (2014) 1.00
Activity-based protein profiling identifies a host enzyme, carboxylesterase 1, which is differentially active during hepatitis C virus replication. J Biol Chem (2010) 0.99
ABHD5/CGI-58 facilitates the assembly and secretion of apolipoprotein B lipoproteins by McA RH7777 rat hepatoma cells. Biochim Biophys Acta (2009) 0.98
Gut triglyceride production. Biochim Biophys Acta (2011) 0.97
Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol (2007) 0.96
Structural and dynamic interfacial properties of the lipoprotein initiating domain of apolipoprotein B. J Lipid Res (2008) 0.95
Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice. J Biol Chem (2010) 0.94
Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. Elife (2015) 0.94
Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB. J Biol Chem (2008) 0.93
Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J Lipid Res (2011) 0.92
Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments. J Lipid Res (2006) 0.92
VASP increases hepatic fatty acid oxidation by activating AMPK in mice. Diabetes (2013) 0.92
Reconstituting initial events during the assembly of apolipoprotein B-containing lipoproteins in a cell-free system. J Mol Biol (2008) 0.91
Insulin-stimulated degradation of apolipoprotein B100: roles of class II phosphatidylinositol-3-kinase and autophagy. PLoS One (2013) 0.91
FoxO1 and hepatic lipid metabolism. Curr Opin Lipidol (2009) 0.91
Protein disulfide isomerases contribute differentially to the endoplasmic reticulum-associated degradation of apolipoprotein B and other substrates. Mol Biol Cell (2011) 0.90
Triacylglycerol hydrolase is localized to the endoplasmic reticulum by an unusual retrieval sequence where it participates in VLDL assembly without utilizing VLDL lipids as substrates. Mol Biol Cell (2004) 0.90
Cadmium-mediated rescue from ER-associated degradation induces expression of its exporter. Proc Natl Acad Sci U S A (2009) 0.90
Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res (2012) 0.90
Opposing roles of cell death-inducing DFF45-like effector B and perilipin 2 in controlling hepatic VLDL lipidation. J Lipid Res (2012) 0.89
Glucosamine-induced endoplasmic reticulum stress attenuates apolipoprotein B100 synthesis via PERK signaling. J Lipid Res (2009) 0.89
Lipid-dependent bidirectional traffic of apolipoprotein B in polarized enterocytes. Mol Biol Cell (2003) 0.89
ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice. J Biol Chem (2013) 0.88
CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). Semin Immunopathol (2013) 0.87
Fatty liver and insulin resistance: not always linked. Trans Am Clin Climatol Assoc (2008) 0.87
Zebrafish as a model for apolipoprotein biology: comprehensive expression analysis and a role for ApoA-IV in regulating food intake. Dis Model Mech (2015) 0.86
Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J Lipid Res (2011) 0.85
The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab (2013) 0.85
Polymorphisms of microsomal triglyceride transfer protein in different hepatitis B virus-infected patients. World J Gastroenterol (2008) 0.84
Arylacetamide deacetylase attenuates fatty-acid-induced triacylglycerol accumulation in rat hepatoma cells. J Lipid Res (2009) 0.84
The topology of the triacylglycerol synthesizing enzyme Lro1 indicates that neutral lipids can be produced within the luminal compartment of the endoplasmatic reticulum: Implications for the biogenesis of lipid droplets. Commun Integr Biol (2011) 0.84
Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling. Arterioscler Thromb Vasc Biol (2011) 0.84
Impact of ER protein homeostasis on metabolism. Diabetes (2013) 0.82
Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor. J Lipid Res (2008) 0.82
Adaptation of enterocytic Caco-2 cells to glucose modulates triacylglycerol-rich lipoprotein secretion through triacylglycerol targeting into the endoplasmic reticulum lumen. Biochem J (2006) 0.82
Apolipoprotein B-containing lipoprotein assembly in microsomal triglyceride transfer protein-deficient McA-RH7777 cells. J Lipid Res (2010) 0.82
Charged amino acid residues 997-1000 of human apolipoprotein B100 are critical for the initiation of lipoprotein assembly and the formation of a stable lipidated primordial particle in McA-RH7777 cells. J Biol Chem (2008) 0.82
Insights from human congenital disorders of intestinal lipid metabolism. J Lipid Res (2014) 0.81
Impact of dietary fat type within the context of altered cholesterol homeostasis on cholesterol and lipoprotein metabolism in the F1B hamster. Metabolism (2010) 0.80
Eucommia ulmoides Oliver extract, aucubin, and geniposide enhance lysosomal activity to regulate ER stress and hepatic lipid accumulation. PLoS One (2013) 0.79
Central nervous system neuropeptide Y signaling via the Y1 receptor partially dissociates feeding behavior from lipoprotein metabolism in lean rats. Am J Physiol Endocrinol Metab (2012) 0.79
Effect of Octreotide on Hepatic Steatosis in Diet-Induced Obesity in Rats. PLoS One (2016) 0.79
Cideb facilitates the lipidation of chylomicrons in the small intestine. J Lipid Res (2014) 0.78
Impact of hepatitis B virus infection on hepatic metabolic signaling pathway. World J Gastroenterol (2016) 0.77
Iron dextran increases hepatic oxidative stress and alters expression of genes related to lipid metabolism contributing to hyperlipidaemia in murine model. Biomed Res Int (2015) 0.77
Exiting from uncharted territory: hepatitis C virus assembles in mouse cell lines. Hepatology (2012) 0.76
Phospholipid transfer protein plays a major role in the initiation of apolipoprotein B-containing lipoprotein assembly in mouse primary hepatocytes. J Biol Chem (2015) 0.76
Very Low Density Lipoprotein Assembly Is Required for cAMP-responsive Element-binding Protein H Processing and Hepatic Apolipoprotein A-IV Expression. J Biol Chem (2016) 0.76
In Vitro Analysis of the Very-Low Density Lipoprotein Export from the Trans-Golgi Network. Curr Protoc Cell Biol (2015) 0.76
Proteomic Analysis of One-carbon Metabolism-related Marker in Liver of Rat Offspring. Mol Cell Proteomics (2015) 0.76
Bax Inhibitor-1 regulates hepatic lipid accumulation via ApoB secretion. Sci Rep (2016) 0.75
A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. Cell Stem Cell (2017) 0.75
Cadmium and Secondary Structure-dependent Function of a Degron in the Pca1p Cadmium Exporter. J Biol Chem (2016) 0.75
A high-fat, high-saturated fat diet decreases insulin sensitivity without changing intra-abdominal fat in weight-stable overweight and obese adults. Eur J Nutr (2015) 0.75
Hold the antioxidants and improve plasma lipids? J Clin Invest (2004) 0.75
Effects of Securigera securidaca Extract on Lipolysis and Adipogenesis in Diabetic Rats. Cholesterol (2014) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab (2008) 7.97
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2011) 6.36
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest (2008) 2.58
Diabetic dyslipidemia. Endocrinol Metab Clin North Am (2006) 2.35
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther (2007) 1.86
C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes (2010) 1.86
Prevention or delay of type 2 diabetes. Diabetes Care (2004) 1.73
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care (2013) 1.71
Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res (2005) 1.68
Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest (2004) 1.67
Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem (2006) 1.63
Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health. Sleep (2010) 1.59
CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes (2012) 1.56
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab (2011) 1.53
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail (2010) 1.49
Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J Biol Chem (2003) 1.37
Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol (2008) 1.35
Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. J Clin Invest (2012) 1.28
Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology (2006) 1.27
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med (2013) 1.23
Understanding interdisciplinary health sciences collaborations: a campus-wide survey of obesity experts. AMIA Annu Symp Proc (2008) 1.22
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care (2012) 1.14
Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol (2011) 1.14
Whole-body insulin resistance in the absence of obesity in FVB mice with overexpression of Dgat1 in adipose tissue. Diabetes (2005) 1.13
Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem (2004) 1.10
DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J Lipid Res (2011) 1.09
Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res (2012) 1.06
Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes. J Biol Chem (2002) 1.02
Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr (2007) 1.01
Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol (2008) 0.99
Cholesterol-lowering benefits of oat-containing cereal in Hispanic americans. J Am Diet Assoc (2005) 0.97
Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol (2007) 0.96
The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism. Ann Med (2004) 0.94
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era. Curr Opin Lipidol (2015) 0.93
Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J Lipid Res (2011) 0.92
Adipose tissue distribution after weight restoration and weight maintenance in women with anorexia nervosa. Am J Clin Nutr (2009) 0.90
Effects of a 1,3-diacylglycerol oil-enriched diet on postprandial lipemia in people with insulin resistance. J Lipid Res (2007) 0.90
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest (2015) 0.88
Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism (2010) 0.88
Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. Rapid Commun Mass Spectrom (2013) 0.86
Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus. J Lipid Res (2009) 0.86
Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results. Arterioscler Thromb Vasc Biol (2008) 0.85
Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J Lipid Res (2011) 0.85
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. J Lipid Res (2005) 0.85
Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opin Pharmacother (2011) 0.84
Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling. Arterioscler Thromb Vasc Biol (2011) 0.84
Translocation efficiency of apolipoprotein B is determined by the presence of beta-sheet domains, not pause transfer sequences. J Biol Chem (2006) 0.84
Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care (2012) 0.81
Gerald M. Reaven, MD: Demonstration of the central role of insulin resistance in type 2 diabetes and cardiovascular disease. Diabetes Care (2014) 0.80
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care (2013) 0.80
Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Am J Clin Nutr (2005) 0.80
Dietary 1,3-diacylglycerol protects against diet-induced obesity and insulin resistance. Metabolism (2007) 0.80
Inhibition of apolipoprotein B synthesis stimulates endoplasmic reticulum autophagy that prevents steatosis. J Clin Invest (2016) 0.79
Ovariectomy leads to increased insulin resistance in human apolipoprotein B transgenic mice lacking brown adipose tissue. Metabolism (2003) 0.79
Effects of triacylglycerol and diacylglycerol oils on blood clearance, tissue uptake, and hepatic apolipoprotein B secretion in mice. J Lipid Res (2007) 0.78
Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet. Metabolism (2011) 0.76
Risk factors common to insulin resistance and atherosclerosis explain why diabetes is a cardiovascular disease. Am J Manag Care (2002) 0.76
Autophagy and cardiometabolic risk factors. Rev Endocr Metab Disord (2014) 0.76
Monthly haemostatic factor variability in women and men. Eur J Clin Invest (2014) 0.75
[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. Turk Kardiyol Dern Ars (2015) 0.75
Dyslipidemia of insulin resistance syndrome explained; need for treatment to reduce risk emphasized. Am J Manag Care (2002) 0.75
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest (2016) 0.75
Cholesterol management: targeting a lower low-density lipoprotein cholesterol concentration increases adult treatment panel-III goal attainment. Am J Cardiol (2006) 0.75